Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
109
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

Nobuki Furubayashi1 Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9159-493XView further author information
ORCID Icon,
Takahito Negishi1 Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information
,
Naotaka Sakamoto2 Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, JapanView further author information
,
Hozumi Shimokawa3 Department of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, JapanView further author information
,
Futoshi Morokuma4 Department of Urology, Saga-ken Medical Centre Koseikan, Saga, JapanORCID Iconhttps://orcid.org/0000-0002-3798-8644View further author information
ORCID Icon,
Yoohyun Song5 Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JapanView further author information
,
Yoshifumi Hori6 Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JapanView further author information
,
Toshihisa Tomoda7 Department of Urology, Oita Prefectural Hospital, Oita, JapanORCID Iconhttps://orcid.org/0000-0002-9346-1900View further author information
ORCID Icon,
Noriaki Tokuda4 Department of Urology, Saga-ken Medical Centre Koseikan, Saga, JapanView further author information
,
Narihito Seki5 Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JapanView further author information
,
Kentaro Kuroiwa6 Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JapanView further author information
&
Motonobu Nakamura1 Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information
 show all
Pages 1981-1988 | Published online: 18 Mar 2021

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Makito Miyake, Nobutaka Nishimura, Takuto Shimizu, Mikiko Ohnishi, Masaomi Kuwada, Yoshitaka Itami, Takeshi Inoue, Kenta Ohnishi, Yoshihiro Matsumoto, Takanori Yoshida, Yoshihiro Tatsumi, Masatake Shinohara, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Tomomi Fujii, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data. Cancer Management and Research 14, pages 623-635.
Read now

Articles from other publishers (5)

Liangshan Da, Ziting Qu, Congjun Zhang, Yuanyuan Shen, Wei Huang, Yiyin Zhang & Kangsheng Gu. (2023) Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment. Frontiers in Oncology 13.
Crossref
Kota Umeda, Nobuyuki Tanaka, Yota Yasumizu, Toshikazu Takeda, Kazuhiro Matsumoto, Shinya Morita, Takeo Kosaka, Ryuichi Mizuno & Mototsugu Oya. (2023) Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab. Clinical Genitourinary Cancer 21:1, pages 128-135.
Crossref
Nobutaka Nishimura, Makito Miyake, Takuto Shimizu, Toshihiko Matsubara, Tatsuki Miyamoto, Keichi Sakamoto, Atsushi Yamada, Yoshihiro Matsumoto, Motokiyo Yoshikawa, Kazuki Ichikawa, Chihiro Omori, Fumisato Maesaka, Yuki Oda, Keisuke Kiba, Atsushi Tomioka, Yukinari Hosokawa, Masahiro Tanaka, Takeshi Otani & Kiyohide Fujimoto. (2022) First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer. International Journal of Clinical Oncology 27:11, pages 1733-1741.
Crossref
Makito Miyake, Takuto Shimizu, Nobutaka Nishimura, Keisuke Kiba, Fumisato Maesaka, Yuki Oda, Akira Tachibana, Mitsuru Tomizawa, Chihiro Ohmori, Yoshiaki Matsumura, Kazuki Ichikawa, Shinichiro Mizobuchi, Takanosuke Yoshikawa, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer 20:2, pages 196.e1-196.e9.
Crossref
Takuto Shimizu, Makito Miyake, Nobutaka Nishimura, Kuniaki Inoue, Koyo Fujii, Yusuke Iemura, Kazuki Ichikawa, Chihiro Omori, Mitsuru Tomizawa, Fumisato Maesaka, Yuki Oda, Tatsuki Miyamoto, Keiichi Sakamoto, Keisuke Kiba, Masahiro Tanaka, Nobuo Oyama, Eijiro Okajima, Ken Fujimoto, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Cancers 14:7, pages 1735.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.